Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel Earum Pharmaceuticals Ltd - 542724 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to the captioned subject, kindly find attached herewith Annual Secretarial Compliance Report issued under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the year ended on 31st March, 2021. Kindly take the same on your record and oblige us. Thanking You Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, we hereby inform you that Mr. Bhavesh N. Sonesara has resigned from the position of the Independent Director of the Company with effect from 9th June, 2022. Further, the Company has received confirmation from Mr. Bhavesh N. Sonesara that there are no other material reasons for his resignation other than those which are provided in the resignation letter. Sr. No. Disclosure Requirements Details 1. Reason for Resignation Due to other professional commitments, Mr. Bhavesh N. Sonesara has expressed his intention to resign from the post of Independent Director of the Company w.e.f. 9th June, 2022. 2. Date of Resignation 9th June, 2022 Earum Pharmaceuticals Ltd - 542724 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayEarum Pharmaceuticals Ltd 2CINL24230GJ2012PLC071299 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 9.73 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: BHUMISHTH NARENDRABHAI PATEL Designation: Compliance Officer EmailId: cs@earumpharma.com Name of the Chief Financial Officer: PAYAL BHUMISHTH PATEL Designation: Chief Financial Officer EmailId: cs@earumpharma.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Earum Pharmaceuticals Ltd - 542724 - Submission Of Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2022
With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on 31st March, 2022. Kindly take the same on your record and oblige us. Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Payal B Patel Earum Pharmaceuticals Ltd - 542724 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhumishth N Patel Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, we hereby inform you that Ms. Priya Raval, has resigned from the post of Company Secretary & Compliance Officer of the Company with effect from 28th April, 2022.